Browse drugs

…BL/6-hNectin4, or WT mice. Tumor-bearing mice received T-Dxd or enfortumab vedotin monotherapy, or combination therapy with anti-PD1.Results The l…

…ion.Conclusions Taken together, the intralymphatic injection of H101 combined with chemotherapy and immunotherapy may represent a pr…

…s increased with NaCN treatment ( figure 1A) and decreased with 2-DG treatment (figure 1B), as expected, suggesting that our model i…

…ignaling was enriched in these inflammatory monocytes following leuprolide treatment in both patients and mice. Further, we identified an …

…im T-Y, Tai WMD, Kang Y-K, Lau G, et al. Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: resu…

…liferation when added at hyperosmotic concentrations. Uniquely, Neu5Ac simultaneously promoted T cell expansion while suppressing term…

…nti-tumor efficacy with favorable toxicity profiles.Conclusions ABN202 (αTROP2) demonstrates potent anti-tumor efficacy in acidic tumor microen…

…d40, Cd274).Conclusions Our results demonstrate that RT induces TIMP-1 secretion by glioblastoma cells and increases expression of its…

…esized that combining the STING agonist ADU-S100 with the BRAFi vemurafenib would synergistically augment NK cell cytotoxicity and promote …

…c single-stranded DNA and immunomodulator. In the murine tumor, CpG ODN suppresses tumor growth and increases CD8 + T cell infiltration…

… Our Lab previously showed that a small molecule STING agonist (ADU-S100), can turn on the pathway and improve survival in mouse GBM mod…

…reast tumors than T-DXd.Conclusions The advanced ADC, utilizing Exatecan and a super-hydrophilic polymer carrier, achieved ultra-high dr…